Two Orphan Drug Designations Granted for Reviroc in NHL

Publication
Article
OncologyONCOLOGY Vol 22 No 14
Volume 22
Issue 14

The biopharmaceutical company Kiadis Pharma recently announced that the US Food and Drug Administration (FDA) has granted its product Reviroc orphan drug designations for the treatment of two types of non-Hodgkin lymphoma (NHL)-one for diffuse large B-cell lymphoma and the other for the treatment of follicular lymphoma.

The biopharmaceutical company Kiadis Pharma recently announced that the US Food and Drug Administration (FDA) has granted its product Reviroc orphan drug designations for the treatment of two types of non-Hodgkin lymphoma (NHL)-one for diffuse large B-cell lymphoma and the other for the treatment of follicular lymphoma. Reviroc is under development for the elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients.

Articles in this issue
The Absent-Minded Professor: An Unusual Complication of Melanoma
The Absent-Minded Professor: An Unusual Complication of Melanoma
Inflammatory Breast Cancer: A Complex Disease
Defining the IBC Phenotype
Acupuncture
Acupuncture
Two Orphan Drug Designations Granted for Reviroc in NHL
NDA Submitted for Trabectedin to Treat Relapsed Ovarian Cancer
FDA Considers Update for Tanning Bed Labels
FDA Approves New Imaging System to Enhance Cervical Cancer Detection
Fostamatinib Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia
Dexamethasone in Induction Can Eliminate One-Third of All Relapses in Childhood Acute Lymphoblastic Leukemia
Novel Antifolate Pralatrexate Shows Promise in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Alemtuzumab May Lead to Longer Overall Survival in CLL Patients With Poor Prognostic Factors
21st Century Challenge of Ovarian Cancer in the Elderly
21st Century Challenge of Ovarian Cancer in the Elderly
Molecular Determinants of the Inflammatory Breast Cancer Phenotype
Related Videos
Related Content
69 The Importance of Tri-Modality Therapy for De Novo Stage IV Invasive Lobular Carcinoma (ILC) Presenting With Bone-Only Metastases

69 The Importance of Tri-Modality Therapy for De Novo Stage IV Invasive Lobular Carcinoma (ILC) Presenting With Bone-Only Metastases

April 21st 2024
Article
Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

April 19th 2024
Article

Omid Hamid, MD, gives his perspective on the use of tumor-infiltrating lymphocyte therapy for patients with melanoma.

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.

The Impact of CAR T-Cell Therapy on Hematological Malignancies

The Impact of CAR T-Cell Therapy on Hematological Malignancies

March 11th 2024
Article

Jae Park, MD, discussed the use of CAR T-cell therapy across the hematologic malignancies space.

HER3-DXd May Lead to an Additional Treatment Option in EGFR+ NSCLC

HER3-DXd May Lead to an Additional Treatment Option in EGFR+ NSCLC

March 10th 2024
Article

Helena A. Yu, MD, and Sandip P. Patel, MD, reviewed the use of patritumab deruxtecan, which was assessed in the phase 2 HERTHENA-Lung01 trial.